Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2(+) Breast Cancers: Implications to the ExteNET Trial

导出原文传递

翻译打印收藏纠错

作者： Sudhan, Dhivya R. ^[1] ; Schwarz, Luis J. ^[2] ; Guerrero-Zotano, Angel ^[3] ; Formisano, Luigi ; Nixon, Mellissa J. ; Croessmann, Sarah ; Ericsson, Paula I. Gonzalez ; Sanders, Melinda ; Balko, Justin M. ; Avogadri-Connors, Francesca ; Cutler, Richard E. ; Lalani, Alshad S. ; Bryce, Richard ; Auerbach, Alan ; Arteaga, Carlos L.

作者单位： Puma Biotechnol Inc, Los Angeles, CA USA ^[1] Vanderbilt Univ, Med Ctr, Breast Canc Program, Vanderbilt Ingram Canc Ctr, Nashville, TN USA ^[2] Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Ingram Canc Ctr, Nashville, TN USA ^[3]

发布时间 2019-08-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical cancer research

2019年25卷2期

771-783页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2(+) Breast Cancers: Implications to the ExteNET Trial

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2(+) Breast Cancers: Implications to the ExteNET Trial

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除